Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sitagliptin

- PMLiVE

Lilly partners with GSK and Vir on COVID-19 antibody study

Study will test Lilly's bamlanivimab with GSK/Vir’s VIR-7831

- PMLiVE

Eli Lilly’s COVID-19 antibody combination reduces risk of hospitalisations and death

High-risk patients treated with the two drugs had a 70% reduction in hospitalisation and death

- PMLiVE

Merck ends its COVID-19 vaccine programme after disappointing early trial results

Immune responses were inferior to levels observed in recovered COVID-19 patients

- PMLiVE

Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%

Bamlanivimab-treated care home residents and staff had a significant reduction in COVID-19 risk

- PMLiVE

Merck’s appeal to restore hepatitis C patent verdict against Gilead fails

US Supreme Court rejects Merck’s appeal over patent dispute verdict of $2.54bn

- PMLiVE

Lilly partners with Merus on development of bispecific antibodies for cancer

As part of the deal, Merus could receive a total of up to around $1.6bn for three products

- PMLiVE

Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes

Drug demonstrated a 'significant' slowing of cognitive decline

- PMLiVE

Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

Acquisition includes a number of candidates for neurodegenerative diseases

- PMLiVE

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development

- PMLiVE

US secures 650,000 additional doses of Lilly’s COVID-19 antibody

This takes the total purchased amount to 950,000 doses

- PMLiVE

Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA

If approved, this vaccine will closely challenge Pfizer's Prevnar-13

- PMLiVE

Lilly links up with Precision BioSciences in genome editing deal

Precision will receive an upfront cash payment of $100m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links